Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Sponsor: Scios, Inc.
Terminated
DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment
Other terminated trials from Scios, Inc.
More terminations from Scios, Inc.
A PHASE2 clinical study on Cardiac Transplantation and Congestive Heart Failure, this trial is terminated or withdrawn. The trial is conducted by Scios, Inc. and has accumulated 11 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Scios, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .